[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2150404T3 - Composiciones farmaceuticas de tizoxanida y nitozoxanida. - Google Patents

Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Info

Publication number
ES2150404T3
ES2150404T3 ES98920285T ES98920285T ES2150404T3 ES 2150404 T3 ES2150404 T3 ES 2150404T3 ES 98920285 T ES98920285 T ES 98920285T ES 98920285 T ES98920285 T ES 98920285T ES 2150404 T3 ES2150404 T3 ES 2150404T3
Authority
ES
Spain
Prior art keywords
tizoxanida
nitozoxanida
pharmaceutical compositions
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98920285T
Other languages
English (en)
Other versions
ES2150404T1 (es
Inventor
Jean-Francois Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2150404(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/852,447 external-priority patent/US5968961A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of ES2150404T1 publication Critical patent/ES2150404T1/es
Application granted granted Critical
Publication of ES2150404T3 publication Critical patent/ES2150404T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para administración oral caracterizada porque comprende como agente activo al menos un compuesto seleccionado del grupo integrado por: el compuesto de fórmula (I) y el compuesto de la fórmula (II).
ES98920285T 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y nitozoxanida. Expired - Lifetime ES2150404T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (2)

Publication Number Publication Date
ES2150404T1 ES2150404T1 (es) 2000-12-01
ES2150404T3 true ES2150404T3 (es) 2003-07-01

Family

ID=27420362

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02002887T Expired - Lifetime ES2232687T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.
ES98920285T Expired - Lifetime ES2150404T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02002887T Expired - Lifetime ES2232687T3 (es) 1997-05-07 1998-05-06 Composiciones farmaceuticas de tizoxanida y/o nitazoxanida.

Country Status (35)

Country Link
EP (2) EP1005342B1 (es)
JP (1) JP3739802B2 (es)
KR (2) KR100576646B1 (es)
CN (2) CN100515420C (es)
AP (1) AP1103A (es)
AR (1) AR057242A2 (es)
AT (2) ATE281166T1 (es)
AU (1) AU740022B2 (es)
BG (2) BG109365A (es)
BR (1) BR9808722A (es)
CA (2) CA2418634C (es)
CZ (2) CZ298270B6 (es)
DE (2) DE69827417T2 (es)
DK (2) DK1222921T3 (es)
EA (2) EA002920B1 (es)
EE (1) EE04870B1 (es)
ES (2) ES2232687T3 (es)
GE (1) GEP20032970B (es)
HK (1) HK1025907A1 (es)
HU (1) HU229641B1 (es)
IL (2) IL155799A (es)
IS (1) IS2087B (es)
LV (1) LV12492B (es)
ME (1) ME00530B (es)
NO (2) NO313983B1 (es)
NZ (2) NZ513881A (es)
OA (1) OA11169A (es)
PL (1) PL193275B1 (es)
PT (2) PT1005342E (es)
RO (1) RO120605B1 (es)
SI (1) SI20149B (es)
SK (2) SK283946B6 (es)
TR (1) TR199902733T2 (es)
UA (2) UA57079C2 (es)
WO (1) WO1998050035A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EA015560B1 (ru) * 2006-01-09 2011-08-30 Ромарк Лэборетериз, Эл.Си. Способ лечения вирусного гепатита
CN107260695A (zh) * 2009-02-13 2017-10-20 罗马克实验室有限公司 硝唑尼特的控制释放药物剂型
US8846727B2 (en) 2009-05-12 2014-09-30 Romark Laboratories, L.C. Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
KR20170081228A (ko) * 2014-11-11 2017-07-11 로마크 레버러토리즈, 엘.씨. 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
KR20200121816A (ko) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2022130406A1 (en) * 2020-12-15 2022-06-23 Cipla Limited Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives

Also Published As

Publication number Publication date
SI20149A (sl) 2000-08-31
ES2150404T1 (es) 2000-12-01
EA002908B1 (ru) 2002-10-31
NO20021832D0 (no) 2002-04-18
EP1005342A4 (en) 2001-02-07
CA2418634A1 (en) 1998-11-12
EE9900578A (et) 2000-08-15
AP9901675A0 (en) 1999-12-31
CA2418634C (en) 2004-10-26
DE69809928T2 (de) 2003-04-24
UA57079C2 (uk) 2003-06-16
KR100576646B1 (ko) 2006-05-08
LV12492A (en) 2000-06-20
BR9808722A (pt) 2000-07-11
BG103958A (en) 2000-07-31
HUP0003330A3 (en) 2002-10-28
IS5223A (is) 1999-10-19
CN1158074C (zh) 2004-07-21
IL132516A0 (en) 2001-03-19
HK1025907A1 (en) 2000-12-01
UA74388C2 (uk) 2005-12-15
NO995406L (no) 2000-01-04
NZ513881A (en) 2002-10-25
GEP20032970B (en) 2003-05-27
NO995406D0 (no) 1999-11-04
CZ391199A3 (cs) 2000-07-12
NO335781B1 (no) 2015-02-16
TR199902733T2 (xx) 2000-03-21
DK1005342T3 (da) 2003-03-24
ATE281166T1 (de) 2004-11-15
ME00530B (me) 2011-10-10
IL155799A (en) 2004-08-31
CA2288003A1 (en) 1998-11-12
EP1222921B1 (en) 2004-11-03
BG64973B1 (bg) 2006-11-30
SK283947B6 (sk) 2004-05-04
EP1222921A1 (en) 2002-07-17
AP1103A (en) 2002-09-04
CZ298269B6 (cs) 2007-08-08
KR20010020322A (ko) 2001-03-15
EE04870B1 (et) 2007-08-15
EA002920B1 (ru) 2002-10-31
IS2087B (is) 2006-03-15
IL132516A (en) 2003-12-10
EA200100956A1 (ru) 2002-02-28
JP2001503067A (ja) 2001-03-06
PT1005342E (pt) 2003-02-28
ES2232687T3 (es) 2005-06-01
LV12492B (en) 2001-01-20
SI20149B (en) 2001-08-31
KR100426657B1 (ko) 2004-04-13
CN1255060A (zh) 2000-05-31
WO1998050035A1 (en) 1998-11-12
NO20021832L (no) 2000-01-04
CN100515420C (zh) 2009-07-22
OA11169A (en) 2003-04-25
SK283946B6 (sk) 2004-05-04
NO313983B1 (no) 2003-01-13
PT1222921E (pt) 2005-02-28
JP3739802B2 (ja) 2006-01-25
IL155799A0 (en) 2003-12-23
AU7289598A (en) 1998-11-27
ATE228839T1 (de) 2002-12-15
BG109365A (en) 2006-08-31
HUP0003330A2 (hu) 2001-05-28
CN1552322A (zh) 2004-12-08
DE69827417D1 (de) 2004-12-09
EP1005342B1 (en) 2002-12-04
PL336805A1 (en) 2000-07-17
CA2288003C (en) 2003-10-21
SK151199A3 (en) 2000-07-11
HU229641B1 (en) 2014-03-28
AR057242A2 (es) 2007-11-21
NZ500149A (en) 2001-11-30
KR20040004544A (ko) 2004-01-13
DK1222921T3 (da) 2005-03-07
EP1005342A1 (en) 2000-06-07
DE69809928D1 (de) 2003-01-16
PL193275B1 (pl) 2007-01-31
CZ298270B6 (cs) 2007-08-08
DE69827417T2 (de) 2005-10-27
RO120605B1 (ro) 2006-05-30
EA199901012A1 (ru) 2000-08-28
AU740022B2 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
GT199900203A (es) Composiciones de celecoxib.
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
ES2159591T3 (es) Composicion de liberacion controlada.
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY129356A (en) Electrospun pharmaceutical compositions
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR9810495A (pt) Composição farmacêutica
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
DE69917796D1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
ECSP003685A (es) Formulaciones orales de liberacion controlada
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration